Header Logo

Connection

Christopher Goetz to Parkinson Disease

Back to Details
This is a "connection" page, showing publications Christopher Goetz has written about Parkinson Disease.
Christopher Goetz
Connection Strength
28.446
Parkinson Disease
  1. Reply to: Comment on "Summing MDS-UPDRS Parts 1?+?2 (Non-motor and Motor Experience of Daily Living): The Patient's Voice". Mov Disord. 2023 08; 38(8):1564.
    View in: PubMed
    Score: 0.471
  2. It Is as It Was: MDS-UPDRS Part III Scores Cannot Be Combined with Other Parts to Give a Valid Sum. Mov Disord. 2023 02; 38(2):342-347.
    View in: PubMed
    Score: 0.450
  3. The plight of loneliness in Parkinson's disease: New opportunities. Parkinsonism Relat Disord. 2022 Dec; 105:145-148.
    View in: PubMed
    Score: 0.446
  4. Reply to: Cognitive Effects of Deep Brain Stimulation in GBA-Related Parkinson's Disease. Ann Neurol. 2022 08; 92(2):345-346.
    View in: PubMed
    Score: 0.436
  5. Parkinson Disease and Subthalamic Nucleus Deep Brain Stimulation: Cognitive Effects in GBA Mutation Carriers. Ann Neurol. 2022 03; 91(3):424-435.
    View in: PubMed
    Score: 0.424
  6. Apathy in Parkinson disease: Why we should care. Neurology. 2020 11 17; 95(20):893-894.
    View in: PubMed
    Score: 0.387
  7. The Evolution-Driven Signature of Parkinson's Disease. Trends Neurosci. 2020 07; 43(7):475-492.
    View in: PubMed
    Score: 0.378
  8. Parkinson's disease: Is it a consequence of human brain evolution? Mov Disord. 2019 04; 34(4):453-459.
    View in: PubMed
    Score: 0.345
  9. What influences placebo and nocebo responses in Parkinson's disease? Mov Disord. 2018 08; 33(8):1204-1212.
    View in: PubMed
    Score: 0.334
  10. Closing the celebration of 200 years of Parkinson's Essay on the Shaking Palsy: Where do we go in the next 200 years? Mov Disord. 2017 12; 32(12):1651-1652.
    View in: PubMed
    Score: 0.316
  11. Gender-, age-, and race/ethnicity-based differential item functioning analysis of the movement disorder society-sponsored revision of the Unified Parkinson's disease rating scale. Mov Disord. 2016 12; 31(12):1865-1873.
    View in: PubMed
    Score: 0.295
  12. Failing as doorman and disc jockey at the same time: Amygdalar dysfunction in Parkinson's disease. Mov Disord. 2016 Jan; 31(1):11-22.
    View in: PubMed
    Score: 0.277
  13. Preface. Mov Disord. 2015 Sep 15; 30(11):1441.
    View in: PubMed
    Score: 0.271
  14. Handling missing values in the MDS-UPDRS. Mov Disord. 2015 Oct; 30(12):1632-8.
    View in: PubMed
    Score: 0.261
  15. Initial management of Parkinson's disease. BMJ. 2014 Dec 19; 349:g6258.
    View in: PubMed
    Score: 0.259
  16. Relationships among cognitive impairment, sleep, and fatigue in Parkinson's disease using the MDS-UPDRS. Parkinsonism Relat Disord. 2014 Nov; 20(11):1135-9.
    View in: PubMed
    Score: 0.253
  17. Comparison of the Movement Disorder Society Parkinson's disease dementia criteria with neuropsychological testing. Mov Disord. 2014 Sep; 29(10):1252-7.
    View in: PubMed
    Score: 0.248
  18. Are patients with Parkinson's disease blind to blindsight? Brain. 2014 Jun; 137(Pt 6):1838-49.
    View in: PubMed
    Score: 0.247
  19. Visuoperceptive region atrophy independent of cognitive status in patients with Parkinson's disease with hallucinations. Brain. 2014 Mar; 137(Pt 3):849-59.
    View in: PubMed
    Score: 0.244
  20. Relationship between the MDS-UPDRS domains and the health-related quality of life of Parkinson's disease patients. Eur J Neurol. 2014 Mar; 21(3):519-24.
    View in: PubMed
    Score: 0.243
  21. I finally see what you see: Parkinson's disease visual hallucinations captured with functional neuroimaging. Mov Disord. 2014 Jan; 29(1):115-7.
    View in: PubMed
    Score: 0.234
  22. Assessing the non-motor symptoms of Parkinson's disease: MDS-UPDRS and NMS Scale. Eur J Neurol. 2015 Jan; 22(1):37-43.
    View in: PubMed
    Score: 0.231
  23. The Parkinson's disease multidisciplinary package. Mov Disord. 2013 May; 28(5):565.
    View in: PubMed
    Score: 0.229
  24. Calibration of unified Parkinson's disease rating scale scores to Movement Disorder Society-unified Parkinson's disease rating scale scores. Mov Disord. 2012 Sep 01; 27(10):1239-42.
    View in: PubMed
    Score: 0.220
  25. Expanded and independent validation of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS). J Neurol. 2013 Jan; 260(1):228-36.
    View in: PubMed
    Score: 0.220
  26. Clinical differences among mild cognitive impairment subtypes in Parkinson's disease. Mov Disord. 2012 Aug; 27(9):1129-36.
    View in: PubMed
    Score: 0.218
  27. Tai chi for patients with Parkinson's disease. N Engl J Med. 2012 05 03; 366(18):1737-8; author reply 1738.
    View in: PubMed
    Score: 0.216
  28. Vibration therapy for Parkinson's disease: Charcot's studies revisited. J Parkinsons Dis. 2012; 2(1):23-7.
    View in: PubMed
    Score: 0.211
  29. Clinical validation of Movement Disorder Society-recommended diagnostic criteria for Parkinson's disease with dementia. Mov Disord. 2012 Feb; 27(2):248-53.
    View in: PubMed
    Score: 0.210
  30. Temporal stability of the Unified Dyskinesia Rating Scale. Mov Disord. 2011 Dec; 26(14):2556-9.
    View in: PubMed
    Score: 0.206
  31. The history of Parkinson's disease: early clinical descriptions and neurological therapies. Cold Spring Harb Perspect Med. 2011 Sep; 1(1):a008862.
    View in: PubMed
    Score: 0.206
  32. Wearing-off scales in Parkinson's disease: critique and recommendations. Mov Disord. 2011 Oct; 26(12):2169-75.
    View in: PubMed
    Score: 0.204
  33. Visual plus nonvisual hallucinations in Parkinson's disease: development and evolution over 10 years. Mov Disord. 2011 Oct; 26(12):2196-200.
    View in: PubMed
    Score: 0.204
  34. An update expert opinion on management and research strategies in Parkinson's disease psychosis. Expert Opin Pharmacother. 2011 Sep; 12(13):2009-24.
    View in: PubMed
    Score: 0.202
  35. Racial differences may influence the role of cholecystokinin polymorphisms in Parkinson's disease hallucinations. Mov Disord. 2011 Aug 01; 26(9):1781-2.
    View in: PubMed
    Score: 0.201
  36. Scales to assess sleep impairment in Parkinson's disease: critique and recommendations. Mov Disord. 2010 Dec 15; 25(16):2704-16.
    View in: PubMed
    Score: 0.196
  37. Hallucinations and sleep disorders in PD: ten-year prospective longitudinal study. Neurology. 2010 Nov 16; 75(20):1773-9.
    View in: PubMed
    Score: 0.194
  38. Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease. Mov Disord. 2010 Sep 15; 25(12):1801-8.
    View in: PubMed
    Score: 0.193
  39. Teaching program for the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale: (MDS-UPDRS). Mov Disord. 2010 Jul 15; 25(9):1190-4.
    View in: PubMed
    Score: 0.190
  40. New developments in depression, anxiety, compulsiveness, and hallucinations in Parkinson's disease. Mov Disord. 2010; 25 Suppl 1:S104-9.
    View in: PubMed
    Score: 0.184
  41. [Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS): a new scale for the evaluation of Parkinson's disease]. Rev Neurol (Paris). 2010 Jan; 166(1):1-4.
    View in: PubMed
    Score: 0.182
  42. Jean-Martin Charcot and his vibratory chair for Parkinson disease. Neurology. 2009 Aug 11; 73(6):475-8.
    View in: PubMed
    Score: 0.179
  43. Hallucinations in Parkinson disease. Nat Rev Neurol. 2009 Jun; 5(6):331-42.
    View in: PubMed
    Score: 0.176
  44. Dysautonomia rating scales in Parkinson's disease: sialorrhea, dysphagia, and constipation--critique and recommendations by movement disorders task force on rating scales for Parkinson's disease. Mov Disord. 2009 Apr 15; 24(5):635-46.
    View in: PubMed
    Score: 0.175
  45. Parkinson's disease dementia: definitions, guidelines, and research perspectives in diagnosis. Ann Neurol. 2008 Dec; 64 Suppl 2:S81-92.
    View in: PubMed
    Score: 0.170
  46. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008 Nov 15; 23(15):2129-70.
    View in: PubMed
    Score: 0.170
  47. Apathy and anhedonia rating scales in Parkinson's disease: critique and recommendations. Mov Disord. 2008 Oct 30; 23(14):2004-14.
    View in: PubMed
    Score: 0.169
  48. Anxiety rating scales in Parkinson's disease: critique and recommendations. Mov Disord. 2008 Oct 30; 23(14):2015-25.
    View in: PubMed
    Score: 0.169
  49. The placebo treatments in neurosciences: New insights from clinical and neuroimaging studies. Neurology. 2008 Aug 26; 71(9):677-84.
    View in: PubMed
    Score: 0.167
  50. Antipsychotic medication treatment for mild hallucinations in Parkinson's disease: Positive impact on long-term worsening. Mov Disord. 2008 Aug 15; 23(11):1541-5.
    View in: PubMed
    Score: 0.167
  51. Evaluating Parkinson's disease patients at home: utility of self-videotaping for objective motor, dyskinesia, and ON-OFF assessments. Mov Disord. 2008 Jul 30; 23(10):1479-82.
    View in: PubMed
    Score: 0.166
  52. Visual hallucinations and symptoms of REM sleep behavior disorder in Parkinsonian tauopathies. Int J Geriatr Psychiatry. 2008 Jun; 23(6):598-603.
    View in: PubMed
    Score: 0.164
  53. Placebo influences on dyskinesia in Parkinson's disease. Mov Disord. 2008 Apr 15; 23(5):700-7.
    View in: PubMed
    Score: 0.163
  54. Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions. Mov Disord. 2008 Apr 15; 23(5):690-9.
    View in: PubMed
    Score: 0.163
  55. Scales to assess psychosis in Parkinson's disease: Critique and recommendations. Mov Disord. 2008 Mar 15; 23(4):484-500.
    View in: PubMed
    Score: 0.162
  56. Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group. Mov Disord. 2007 Jun 15; 22(8):1061-8.
    View in: PubMed
    Score: 0.154
  57. Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord. 2007 Jun 15; 22(8):1077-92.
    View in: PubMed
    Score: 0.154
  58. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Mov Disord. 2007 Jan 15; 22(2):179-86.
    View in: PubMed
    Score: 0.149
  59. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord. 2007 Jan; 22(1):41-7.
    View in: PubMed
    Score: 0.149
  60. Motor function in Parkinson's disease and supranuclear palsy: simultaneous factor analysis of a clinical scale in several populations. BMC Med Res Methodol. 2006 Jun 13; 6:26.
    View in: PubMed
    Score: 0.143
  61. Does seasonal variation affect hallucinations in PD? A longitudinal study. Mov Disord. 2006 Jun; 21(6):863-5.
    View in: PubMed
    Score: 0.143
  62. Safety of rasagiline in elderly patients with Parkinson disease. Neurology. 2006 May 09; 66(9):1427-9.
    View in: PubMed
    Score: 0.143
  63. The malignant course of "benign hallucinations" in Parkinson disease. Arch Neurol. 2006 May; 63(5):713-6.
    View in: PubMed
    Score: 0.142
  64. Age-related influences on the clinical characteristics of new-onset hallucinations in Parkinson's disease patients. Mov Disord. 2006 Feb; 21(2):267-70.
    View in: PubMed
    Score: 0.140
  65. What's new? Clinical progression and staging of Parkinson's disease. J Neural Transm Suppl. 2006; (70):305-8.
    View in: PubMed
    Score: 0.139
  66. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord. 2005 May; 20(5):523-39.
    View in: PubMed
    Score: 0.133
  67. Hallucinations and sleep disorders in PD: six-year prospective longitudinal study. Neurology. 2005 Jan 11; 64(1):81-6.
    View in: PubMed
    Score: 0.130
  68. Movement disorders: understanding clinical trials. Lancet Neurol. 2005 Jan; 4(1):5-6.
    View in: PubMed
    Score: 0.130
  69. Assuring interrater reliability for the UPDRS motor section: utility of the UPDRS teaching tape. Mov Disord. 2004 Dec; 19(12):1453-6.
    View in: PubMed
    Score: 0.129
  70. Short-term and practice effects of metronome pacing in Parkinson's disease patients with gait freezing while in the 'on' state: randomized single blind evaluation. Parkinsonism Relat Disord. 2004 Dec; 10(8):507-10.
    View in: PubMed
    Score: 0.129
  71. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord. 2004 Sep; 19(9):1020-8.
    View in: PubMed
    Score: 0.127
  72. Re: UPDRS: Status and recommendations. Mov Disord. 2004 May; 19(5):605.
    View in: PubMed
    Score: 0.124
  73. Standardized training tools for the UPDRS activities of daily living scale: newly available teaching program. Mov Disord. 2003 Dec; 18(12):1455-8.
    View in: PubMed
    Score: 0.120
  74. Wheeled and standard walkers in Parkinson's disease patients with gait freezing. Parkinsonism Relat Disord. 2003 Oct; 10(1):9-14.
    View in: PubMed
    Score: 0.119
  75. Impact of placebo assignment in clinical trials of Parkinson's disease. Mov Disord. 2003 Oct; 18(10):1146-9.
    View in: PubMed
    Score: 0.119
  76. Coping strategies for visual hallucinations in Parkinson's disease. Mov Disord. 2003 Jul; 18(7):831-2.
    View in: PubMed
    Score: 0.117
  77. Summing MDS-UPDRS Parts 1?+?2 (Non-motor and Motor Experience of Daily Living): The Patient's Voice. Mov Disord. 2023 07; 38(7):1363-1364.
    View in: PubMed
    Score: 0.115
  78. Parkinson disease with old-age onset: a comparative study with subjects with middle-age onset. Arch Neurol. 2003 Apr; 60(4):529-33.
    View in: PubMed
    Score: 0.115
  79. An open label, non-randomized study assessing a prebiotic fiber intervention in a small cohort of Parkinson's disease participants. Nat Commun. 2023 02 18; 14(1):926.
    View in: PubMed
    Score: 0.114
  80. Cross-Cultural Differences in Patient Perceptions of Dyskinesia in Parkinson's Disease. Mov Disord. 2023 04; 38(4):688-692.
    View in: PubMed
    Score: 0.113
  81. Using Movement Disorder Society Unified Parkinson's Disease Rating Scale Parts 2 and 3 Simultaneously: Combining the Patient Voice with Clinician Ratings. Mov Disord. 2023 03; 38(3):453-463.
    View in: PubMed
    Score: 0.113
  82. Treatment of advanced Parkinson's disease: an evidence-based analysis. Adv Neurol. 2003; 91:213-28.
    View in: PubMed
    Score: 0.113
  83. Jean-Martin Charcot and the aging brain. Arch Neurol. 2002 Nov; 59(11):1821-4.
    View in: PubMed
    Score: 0.112
  84. Intestinal microbiota and neuroinflammation in Parkinson's disease: At the helm of the gut-brain axis. Int Rev Neurobiol. 2022; 167:81-99.
    View in: PubMed
    Score: 0.110
  85. Progressive worsening of spatial and chromatic processing deficits in Parkinson disease. Arch Neurol. 2002 Aug; 59(8):1249-52.
    View in: PubMed
    Score: 0.110
  86. Dissecting the Domains of Parkinson's Disease: Insights from Longitudinal Item Response Theory Modeling. Mov Disord. 2022 09; 37(9):1904-1914.
    View in: PubMed
    Score: 0.109
  87. Resolving Missing Data from the Movement Disorder Society Unified Parkinson's Disease Rating Scale: Implications for Telemedicine. Mov Disord. 2022 08; 37(8):1749-1755.
    View in: PubMed
    Score: 0.109
  88. Gut microbial metabolites in Parkinson's disease: Association with lifestyle, disease characteristics, and treatment status. Neurobiol Dis. 2022 08; 170:105780.
    View in: PubMed
    Score: 0.108
  89. Gut-Brain Communication in Parkinson's Disease: Enteroendocrine Regulation by GLP-1. Curr Neurol Neurosci Rep. 2022 07; 22(7):335-342.
    View in: PubMed
    Score: 0.108
  90. Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics. Neurology. 2002 May 14; 58(9):1418-22.
    View in: PubMed
    Score: 0.108
  91. Placebo-associated improvements in motor function: comparison of subjective and objective sections of the UPDRS in early Parkinson's disease. Mov Disord. 2002 Mar; 17(2):283-8.
    View in: PubMed
    Score: 0.107
  92. Validation of the Arabic Version of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale. Mov Disord. 2022 04; 37(4):826-841.
    View in: PubMed
    Score: 0.107
  93. Rating scales for medication adherence in people living with Parkinson's disease: a systematic review protocol. JBI Evid Synth. 2022 01 01; 20(1):260-269.
    View in: PubMed
    Score: 0.105
  94. Prospective longitudinal assessment of hallucinations in Parkinson's disease. Neurology. 2001 Dec 11; 57(11):2078-82.
    View in: PubMed
    Score: 0.105
  95. Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial. JAMA. 2021 09 14; 326(10):926-939.
    View in: PubMed
    Score: 0.103
  96. Early morning off-medication dyskinesias, dystonia, and choreic subtypes. Arch Neurol. 2001 Sep; 58(9):1379-82.
    View in: PubMed
    Score: 0.103
  97. Prognostic Modeling of Parkinson's Disease Progression Using Early Longitudinal Patterns of Change. Mov Disord. 2021 12; 36(12):2853-2861.
    View in: PubMed
    Score: 0.102
  98. Validation of the Polish version of the Unified Dyskinesia Rating Scale (UDysRS). Neurol Neurochir Pol. 2021; 55(2):186-194.
    View in: PubMed
    Score: 0.099
  99. Genetic variation analysis in parkinson disease patients with and without hallucinations: case-control study. Arch Neurol. 2001 Feb; 58(2):209-13.
    View in: PubMed
    Score: 0.099
  100. The history of Parkinson's disease: part 2 of the MDS-sponsored History of Movement Disorders Exhibit, Barcelona, June, 2000. Mov Disord. 2001 Jan; 16(1):156-61.
    View in: PubMed
    Score: 0.098
  101. In Support of Electronic Versions of Movement Disorder Society Rating Scales. Mov Disord. 2021 01; 36(1):270-271.
    View in: PubMed
    Score: 0.098
  102. COVID-19 Vaccination for Persons with Parkinson's Disease: Light at the End of the Tunnel? J Parkinsons Dis. 2021; 11(1):3-8.
    View in: PubMed
    Score: 0.098
  103. Menstrual-related changes in motoric function in women with Parkinson's disease. Neurology. 2000 Nov 28; 55(10):1572-5.
    View in: PubMed
    Score: 0.098
  104. Acute orthostatic hypotension when starting dopamine agonists in Parkinson's disease. Arch Neurol. 2000 Oct; 57(10):1461-3.
    View in: PubMed
    Score: 0.097
  105. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology. 2000 Sep 26; 55(6):789-94.
    View in: PubMed
    Score: 0.097
  106. Visual hallucinations induced by deep brain stimulation in Parkinson's disease. Clin Neuropharmacol. 2000 Sep-Oct; 23(5):287-9.
    View in: PubMed
    Score: 0.096
  107. Validation of the Hebrew Version of the Unified Dyskinesia Rating Scale. Neuroepidemiology. 2020; 54(4):356-362.
    View in: PubMed
    Score: 0.095
  108. Item Response Theory Analysis of the MDS-UPDRS Motor Examination: Tremor vs. Nontremor Items. Mov Disord. 2020 09; 35(9):1587-1595.
    View in: PubMed
    Score: 0.094
  109. Differential progression of motor impairment in levodopa-treated Parkinson's disease. Mov Disord. 2000 May; 15(3):479-84.
    View in: PubMed
    Score: 0.094
  110. Impaired frontostriatal cognitive functioning following posteroventral pallidotomy in advanced Parkinson's disease. Brain Cogn. 2000 Apr; 42(3):348-63.
    View in: PubMed
    Score: 0.093
  111. Neuropsychological and behavioral aspects of transplants in Parkinson's disease and Huntington's disease. Brain Cogn. 2000 Mar; 42(2):294-306.
    View in: PubMed
    Score: 0.093
  112. [Visual hallucinations in Parkinson and Charles Bonnet Syndrome patients. A phenomenological and pathogenetic comparison]. Fortschr Neurol Psychiatr. 2000 Mar; 68(3):129-36.
    View in: PubMed
    Score: 0.093
  113. Objective changes in motor function during placebo treatment in PD. Neurology. 2000 Feb 08; 54(3):710-4.
    View in: PubMed
    Score: 0.092
  114. Decreased color discrimination and contrast sensitivity in Parkinson's disease. J Neurol Sci. 2000 Jan 01; 172(1):7-11.
    View in: PubMed
    Score: 0.092
  115. Sex differences by design and outcome in the Safety of Urate Elevation in PD (SURE-PD) trial. Neurology. 2019 10 01; 93(14):e1328-e1338.
    View in: PubMed
    Score: 0.090
  116. Successful use of the Unified Dyskinesia Rating Scale regardless of PD- or dyskinesia-duration. Parkinsonism Relat Disord. 2019 10; 67:113-116.
    View in: PubMed
    Score: 0.090
  117. Parkinson's disease. Clin Neuropharmacol. 1999 Jul-Aug; 22(4):184-91.
    View in: PubMed
    Score: 0.089
  118. Scales to assess impulsive and compulsive behaviors in Parkinson's disease: Critique and recommendations. Mov Disord. 2019 06; 34(6):791-798.
    View in: PubMed
    Score: 0.088
  119. Switching dopamine agonists in advanced Parkinson's disease: is rapid titration preferable to slow? Neurology. 1999 Apr 12; 52(6):1227-9.
    View in: PubMed
    Score: 0.087
  120. Delayed recognition memory in Parkinson's disease: a role for working memory? Neuropsychologia. 1999 Apr; 37(4):503-10.
    View in: PubMed
    Score: 0.087
  121. The Parkinson's disease e-diary: Developing a clinical and research tool for the digital age. Mov Disord. 2019 05; 34(5):676-681.
    View in: PubMed
    Score: 0.087
  122. Hallucinations in Parkinson's disease: the clinical syndrome. Adv Neurol. 1999; 80:419-23.
    View in: PubMed
    Score: 0.086
  123. Rating scales for dyskinesias in Parkinson's disease. Mov Disord. 1999; 14 Suppl 1:48-53.
    View in: PubMed
    Score: 0.086
  124. Early dopaminergic drug-induced hallucinations in parkinsonian patients. Neurology. 1998 Sep; 51(3):811-4.
    View in: PubMed
    Score: 0.084
  125. Validation of the MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2018 10; 33(10):1601-1608.
    View in: PubMed
    Score: 0.084
  126. Movement disorder society criteria for clinically established early Parkinson's disease. Mov Disord. 2018 10; 33(10):1643-1646.
    View in: PubMed
    Score: 0.084
  127. Factor structure of the Unified Parkinson's Disease Rating Scale: Motor Examination section. Mov Disord. 1998 Jul; 13(4):633-6.
    View in: PubMed
    Score: 0.083
  128. Highlights of the North American and European experiences. Neurology. 1998 May; 50(5 Suppl 5):S15-6.
    View in: PubMed
    Score: 0.082
  129. Influence of COMT inhibition on levodopa pharmacology and therapy. Neurology. 1998 May; 50(5 Suppl 5):S26-30.
    View in: PubMed
    Score: 0.082
  130. New lessons from old drugs: amantadine and Parkinson's disease. Neurology. 1998 May; 50(5):1211-2.
    View in: PubMed
    Score: 0.082
  131. Relationship between the MDS-UPDRS and Quality of Life: A large multicenter study of 3206 patients. Parkinsonism Relat Disord. 2018 07; 52:83-89.
    View in: PubMed
    Score: 0.081
  132. Reply: MoCA for cognitive screening in Parkinson's disease: Beware of floor effect. Mov Disord. 2018 03; 33(3):499-500.
    View in: PubMed
    Score: 0.081
  133. Intravenous levodopa in hallucinating Parkinson's disease patients: high-dose challenge does not precipitate hallucinations. Neurology. 1998 Feb; 50(2):515-7.
    View in: PubMed
    Score: 0.080
  134. Global scales for cognitive screening in Parkinson's disease: Critique and recommendations. Mov Disord. 2018 02; 33(2):208-218.
    View in: PubMed
    Score: 0.079
  135. Efficacy of a patient-training videotape on motor fluctuations for on-off diaries in Parkinson's disease. Mov Disord. 1997 Nov; 12(6):1039-41.
    View in: PubMed
    Score: 0.079
  136. Validation of the Hebrew version of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale. Parkinsonism Relat Disord. 2017 Dec; 45:7-12.
    View in: PubMed
    Score: 0.078
  137. Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy. Mov Disord. 2017 Sep; 32(9):1264-1310.
    View in: PubMed
    Score: 0.078
  138. Topiramate as an adjunct to amantadine in the treatment of dyskinesia in parkinson's disease: A randomized, double-blind, placebo-controlled multicenter study. Mov Disord. 2017 09; 32(9):1335-1336.
    View in: PubMed
    Score: 0.077
  139. New strategies with dopaminergic drugs: modified formulations of levodopa and novel agonists. Exp Neurol. 1997 Mar; 144(1):17-20.
    View in: PubMed
    Score: 0.075
  140. Robust graft survival and normalized dopaminergic innervation do not obligate recovery in a Parkinson disease patient. Ann Neurol. 2017 Jan; 81(1):46-57.
    View in: PubMed
    Score: 0.075
  141. Comparison of neuropathology in Parkinson's disease subjects with and without deep brain stimulation. Mov Disord. 2017 02; 32(2):274-277.
    View in: PubMed
    Score: 0.074
  142. Disability Rating Scales in Parkinson's Disease: Critique and Recommendations. Mov Disord. 2016 10; 31(10):1455-1465.
    View in: PubMed
    Score: 0.073
  143. Abolishing the 1-year rule: How much evidence will be enough? Mov Disord. 2016 11; 31(11):1623-1627.
    View in: PubMed
    Score: 0.073
  144. A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease. Mov Disord. 2016 09; 31(9):1373-80.
    View in: PubMed
    Score: 0.071
  145. There is a renaissance of interest in pallidotomy for Parkinson's disease. Nat Med. 1996 May; 2(5):510-4.
    View in: PubMed
    Score: 0.071
  146. The new definition and diagnostic criteria of Parkinson's disease. Lancet Neurol. 2016 05; 15(6):546-8.
    View in: PubMed
    Score: 0.071
  147. Measurement instruments to assess posture, gait, and balance in Parkinson's disease: Critique and recommendations. Mov Disord. 2016 09; 31(9):1342-55.
    View in: PubMed
    Score: 0.070
  148. Parkinson's disease-related fatigue: A case definition and recommendations for clinical research. Mov Disord. 2016 05; 31(5):625-31.
    View in: PubMed
    Score: 0.070
  149. Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial. Ann Neurol. 2015 Aug; 78(2):248-57.
    View in: PubMed
    Score: 0.067
  150. Teaching tape for the motor section of the unified Parkinson's disease rating scale. Mov Disord. 1995 May; 10(3):263-6.
    View in: PubMed
    Score: 0.066
  151. Mortality and hallucinations in nursing home patients with advanced Parkinson's disease. Neurology. 1995 Apr; 45(4):669-71.
    View in: PubMed
    Score: 0.066
  152. Diagnosing PD-MCI by MDS Task Force criteria: how many and which neuropsychological tests? Mov Disord. 2015 Mar; 30(3):402-6.
    View in: PubMed
    Score: 0.065
  153. Akathisia in Parkinson's disease. Mov Disord. 1994 Sep; 9(5):545-9.
    View in: PubMed
    Score: 0.063
  154. Utility of an objective dyskinesia rating scale for Parkinson's disease: inter- and intrarater reliability assessment. Mov Disord. 1994 Jul; 9(4):390-4.
    View in: PubMed
    Score: 0.063
  155. The past, present, and future of telemedicine for Parkinson's disease. Mov Disord. 2014 Jun; 29(7):871-83.
    View in: PubMed
    Score: 0.062
  156. Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Mov Disord. 2014 Apr; 29(4):454-62.
    View in: PubMed
    Score: 0.061
  157. The role of surgery in Parkinson's disease management. Neurology. 1994 Mar; 44(3 Suppl 1):S17-20.
    View in: PubMed
    Score: 0.061
  158. Physical therapy and Parkinson's disease: a controlled clinical trial. Neurology. 1994 Mar; 44(3 Pt 1):376-8.
    View in: PubMed
    Score: 0.061
  159. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. JAMA Neurol. 2014 Feb; 71(2):141-50.
    View in: PubMed
    Score: 0.061
  160. Using cognitive pretesting in scale development for Parkinson's disease: the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) example. J Parkinsons Dis. 2014; 4(3):395-404.
    View in: PubMed
    Score: 0.061
  161. Fetal-tissue transplantation for Parkinson's disease. N Engl J Med. 1993 Nov 11; 329(20):1498; author reply 1499-500.
    View in: PubMed
    Score: 0.060
  162. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology. 1993 Nov; 43(11):2227-9.
    View in: PubMed
    Score: 0.060
  163. Defining optimal cutoff scores for cognitive impairment using Movement Disorder Society Task Force criteria for mild cognitive impairment in Parkinson's disease. Mov Disord. 2013 Dec; 28(14):1972-9.
    View in: PubMed
    Score: 0.060
  164. Movement disorder society unified Parkinson disease rating scale experiences in daily living: longitudinal changes and correlation with other assessments. Mov Disord. 2013 Dec; 28(14):1980-6.
    View in: PubMed
    Score: 0.060
  165. Measurement of costs and scales for outcome evaluation in health economic studies of Parkinson's disease. Mov Disord. 2014 Feb; 29(2):169-76.
    View in: PubMed
    Score: 0.059
  166. The MDS-UPDRS Part II (motor experiences of daily living) resulted useful for assessment of disability in Parkinson's disease. Parkinsonism Relat Disord. 2013 Oct; 19(10):889-93.
    View in: PubMed
    Score: 0.058
  167. Dissociations among daytime sleepiness, nighttime sleep, and cognitive status in Parkinson's disease. Parkinsonism Relat Disord. 2013 Sep; 19(9):806-11.
    View in: PubMed
    Score: 0.058
  168. Diffusion tensor imaging of Parkinson's disease, atypical parkinsonism, and essential tremor. Mov Disord. 2013 Nov; 28(13):1816-22.
    View in: PubMed
    Score: 0.058
  169. Blood levodopa levels and unified Parkinson's disease rating scale function: with and without exercise. Neurology. 1993 May; 43(5):1040-2.
    View in: PubMed
    Score: 0.058
  170. Force control deficits in individuals with Parkinson's disease, multiple systems atrophy, and progressive supranuclear palsy. PLoS One. 2013; 8(3):e58403.
    View in: PubMed
    Score: 0.057
  171. How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson's disease rating scale: comparison with the unified Parkinson's disease rating scale. Mov Disord. 2013 May; 28(5):668-70.
    View in: PubMed
    Score: 0.057
  172. Which dyskinesia scale best detects treatment response? Mov Disord. 2013 Mar; 28(3):341-6.
    View in: PubMed
    Score: 0.057
  173. [Fetal and adrenal transplantation in Parkinson disease: theoretical bases and clinical results]. Bull Soc Sci Med Grand Duche Luxemb. 1993; 130(1):25-36.
    View in: PubMed
    Score: 0.057
  174. Neurosurgical horizons in Parkinson's disease. Neurology. 1993 Jan; 43(1):1-7.
    View in: PubMed
    Score: 0.057
  175. Ideational fluency in Parkinson's disease. Brain Cogn. 1992 Nov; 20(2):236-44.
    View in: PubMed
    Score: 0.056
  176. Validation of the Italian version of the Movement Disorder Society--Unified Parkinson's Disease Rating Scale. Neurol Sci. 2013 May; 34(5):683-7.
    View in: PubMed
    Score: 0.054
  177. Dopaminergic agonists in the treatment of Parkinson's disease. Neurol Clin. 1992 May; 10(2):527-40.
    View in: PubMed
    Score: 0.054
  178. Entorhinal cortex atrophy differentiates Parkinson's disease patients with and without dementia. Mov Disord. 2012 May; 27(6):727-34.
    View in: PubMed
    Score: 0.053
  179. United Parkinson Foundation Neurotransplantation Registry on adrenal medullary transplants: presurgical, and 1- and 2-year follow-up. Neurology. 1991 Nov; 41(11):1719-22.
    View in: PubMed
    Score: 0.052
  180. Subject-investigator reproducibility of the Unified Parkinson's Disease Rating Scale. Parkinsonism Relat Disord. 2012 Mar; 18(3):230-3.
    View in: PubMed
    Score: 0.052
  181. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease. Mov Disord. 2011 Oct; 26 Suppl 3:S2-41.
    View in: PubMed
    Score: 0.052
  182. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. Mov Disord. 2011 Oct; 26 Suppl 3:S42-80.
    View in: PubMed
    Score: 0.052
  183. Validation of the MDS-UPDRS Part I for nonmotor symptoms in Parkinson's disease. Mov Disord. 2012 Jan; 27(1):79-83.
    View in: PubMed
    Score: 0.052
  184. Health-related quality-of-life scales in Parkinson's disease: critique and recommendations. Mov Disord. 2011 Nov; 26(13):2371-80.
    View in: PubMed
    Score: 0.051
  185. The Movement Disorders task force review of dysautonomia rating scales in Parkinson's disease with regard to symptoms of orthostatic hypotension. Mov Disord. 2011 Sep; 26(11):1985-92.
    View in: PubMed
    Score: 0.050
  186. Priorities in Parkinson's disease research. Nat Rev Drug Discov. 2011 May; 10(5):377-93.
    View in: PubMed
    Score: 0.050
  187. Putative chromaffin cell survival and enhanced host-derived TH-fiber innervation following a functional adrenal medulla autograft for Parkinson's disease. Ann Neurol. 1991 Apr; 29(4):405-12.
    View in: PubMed
    Score: 0.050
  188. Effects of head trauma from motor vehicle accidents on Parkinson's disease. Ann Neurol. 1991 Feb; 29(2):191-3.
    View in: PubMed
    Score: 0.049
  189. Dopaminergic agonists in the treatment of Parkinson's disease. Neurology. 1990 Oct; 40(10 Suppl 3):suppl 50-4; discussion 54-7.
    View in: PubMed
    Score: 0.048
  190. A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol. 2010 Aug; 67(8):996-1001.
    View in: PubMed
    Score: 0.048
  191. Task force report on scales to assess dyskinesia in Parkinson's disease: critique and recommendations. Mov Disord. 2010 Jul 15; 25(9):1131-42.
    View in: PubMed
    Score: 0.048
  192. Shaking up the Salpetriere: Jean-Martin Charcot and mercury-induced tremor. Neurology. 2010 May 25; 74(21):1739-42.
    View in: PubMed
    Score: 0.047
  193. Missing pieces in the Parkinson's disease puzzle. Nat Med. 2010 Jun; 16(6):653-61.
    View in: PubMed
    Score: 0.047
  194. Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson's disease. Mov Disord. 2010 May 15; 25(7):805-22.
    View in: PubMed
    Score: 0.047
  195. Adrenal medullary transplant to the striatum of patients with advanced Parkinson's disease: 1-year motor and psychomotor data. Neurology. 1990 Feb; 40(2):273-6.
    View in: PubMed
    Score: 0.046
  196. United Parkinson Foundation Neurotransplantation Registry: multicenter US and Canadian data base, presurgical and 12 month follow-up. Prog Brain Res. 1990; 82:611-7.
    View in: PubMed
    Score: 0.046
  197. Scales to evaluate psychosis in Parkinson's disease. Parkinsonism Relat Disord. 2009 Dec; 15 Suppl 3:S38-41.
    View in: PubMed
    Score: 0.046
  198. Development and progression of motor fluctuations and side effects in Parkinson's disease: comparison of Sinemet CR versus carbidopa/levodopa. Neurology. 1989 Nov; 39(11 Suppl 2):63-6; discussion 72-3.
    View in: PubMed
    Score: 0.045
  199. A longitudinal program for biomarker development in Parkinson's disease: a feasibility study. Mov Disord. 2009 Oct 30; 24(14):2081-90.
    View in: PubMed
    Score: 0.045
  200. Using global statistical tests in long-term Parkinson's disease clinical trials. Mov Disord. 2009 Sep 15; 24(12):1732-9.
    View in: PubMed
    Score: 0.045
  201. Agonist substitution in advanced Parkinson's disease. Neurology. 1989 Aug; 39(8):1121-2.
    View in: PubMed
    Score: 0.045
  202. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients. Clin Neuropharmacol. 2009 Jul-Aug; 32(4):189-92.
    View in: PubMed
    Score: 0.044
  203. Testing objective measures of motor impairment in early Parkinson's disease: Feasibility study of an at-home testing device. Mov Disord. 2009 Mar 15; 24(4):551-6.
    View in: PubMed
    Score: 0.043
  204. [Where are the grafts in Parkinson's disease?]. Rev Prat. 1989 Mar 09; 39(8):675-7.
    View in: PubMed
    Score: 0.043
  205. Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: a double blind video-based analysis. Mov Disord. 2009 Feb 15; 24(3):336-43.
    View in: PubMed
    Score: 0.043
  206. Multicenter study of autologous adrenal medullary transplantation to the corpus striatum in patients with advanced Parkinson's disease. N Engl J Med. 1989 Feb 09; 320(6):337-41.
    View in: PubMed
    Score: 0.043
  207. The Unified Dyskinesia Rating Scale: presentation and clinimetric profile. Mov Disord. 2008 Dec 15; 23(16):2398-403.
    View in: PubMed
    Score: 0.043
  208. Risk factors for progression in Parkinson's disease. Neurology. 1988 Dec; 38(12):1841-4.
    View in: PubMed
    Score: 0.043
  209. Controlled-release carbidopa/levodopa (CR4-Sinemet) in Parkinson's disease patients with and without motor fluctuations. Neurology. 1988 Jul; 38(7):1143-6.
    View in: PubMed
    Score: 0.041
  210. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol. 2008 Jun; 65(6):716-23.
    View in: PubMed
    Score: 0.041
  211. Case 2, 1988. Congenital mental retardation and juvenile parkinsonism. Mov Disord. 1988; 3(4):352-61.
    View in: PubMed
    Score: 0.040
  212. Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord. 2007 Dec; 22(16):2314-24.
    View in: PubMed
    Score: 0.040
  213. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord. 2007 Sep 15; 22(12):1689-707; quiz 1837.
    View in: PubMed
    Score: 0.039
  214. Controlled-release Sinemet. Neurology. 1987 Sep; 37(9):1567-8.
    View in: PubMed
    Score: 0.039
  215. Levodopa-induced dyskinesias. Mov Disord. 2007 Jul 30; 22(10):1379-1389.
    View in: PubMed
    Score: 0.039
  216. Parkinson's disease and motor fluctuations: long-acting carbidopa/levodopa (CR-4-Sinemet). Neurology. 1987 May; 37(5):875-8.
    View in: PubMed
    Score: 0.038
  217. The etiopathogenesis of Parkinson disease and suggestions for future research. Part II. J Neuropathol Exp Neurol. 2007 May; 66(5):329-36.
    View in: PubMed
    Score: 0.038
  218. Progression of Parkinson's disease without levodopa. Neurology. 1987 Apr; 37(4):695-8.
    View in: PubMed
    Score: 0.038
  219. The etiopathogenesis of Parkinson disease and suggestions for future research. Part I. J Neuropathol Exp Neurol. 2007 Apr; 66(4):251-7.
    View in: PubMed
    Score: 0.038
  220. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology. 2007 Mar 13; 68(11):812-9.
    View in: PubMed
    Score: 0.038
  221. Apolipoprotein E gene polymorphism, total plasma cholesterol level, and Parkinson disease dementia. Arch Neurol. 2007 Feb; 64(2):261-5.
    View in: PubMed
    Score: 0.037
  222. Relationships among pain, depression, and sleep alterations in Parkinson's disease. Adv Neurol. 1987; 45:345-7.
    View in: PubMed
    Score: 0.037
  223. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease. Mov Disord. 2006 Dec; 21(12):2078-81.
    View in: PubMed
    Score: 0.037
  224. Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms. J Neurol Sci. 2006 Oct 25; 248(1-2):78-83.
    View in: PubMed
    Score: 0.036
  225. A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations. Arch Neurol. 2006 Feb; 63(2):210-6.
    View in: PubMed
    Score: 0.035
  226. Hallucinations in Parkinson disease in the prelevodopa era. Neurology. 2006 Jan 10; 66(1):93-8.
    View in: PubMed
    Score: 0.035
  227. Charcot on Parkinson's disease. Mov Disord. 1986; 1(1):27-32.
    View in: PubMed
    Score: 0.035
  228. Pain in Parkinson's disease. Mov Disord. 1986; 1(1):45-9.
    View in: PubMed
    Score: 0.035
  229. Autonomic dysfunction in Parkinson's disease. Neurology. 1986 Jan; 36(1):73-5.
    View in: PubMed
    Score: 0.035
  230. Chronic agonist therapy for Parkinson's disease: a 5-year study of bromocriptine and pergolide. Neurology. 1985 May; 35(5):749-51.
    View in: PubMed
    Score: 0.033
  231. Repeated visual hallucinations in Parkinson's disease as disturbed external/internal perceptions: focused review and a new integrative model. Mov Disord. 2005 Feb; 20(2):130-40.
    View in: PubMed
    Score: 0.033
  232. A responsive outcome for Parkinson's disease neuroprotection futility studies. Ann Neurol. 2005 Feb; 57(2):197-203.
    View in: PubMed
    Score: 0.033
  233. Non-linearity of Parkinson's disease progression: implications for sample size calculations in clinical trials. Clin Trials. 2005; 2(6):509-18.
    View in: PubMed
    Score: 0.032
  234. Altered cortical visual processing in PD with hallucinations: an fMRI study. Neurology. 2004 Oct 26; 63(8):1409-16.
    View in: PubMed
    Score: 0.032
  235. Bupropion in Parkinson's disease. Neurology. 1984 Aug; 34(8):1092-4.
    View in: PubMed
    Score: 0.032
  236. Genetic polymorphisms in Parkinson disease subjects with and without hallucinations: an analysis of the cholecystokinin system. Arch Neurol. 2004 Aug; 61(8):1280-4.
    View in: PubMed
    Score: 0.032
  237. Apolipoprotein E controls the risk and age at onset of Parkinson disease. Neurology. 2004 Jun 08; 62(11):2005-9.
    View in: PubMed
    Score: 0.031
  238. Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study). Clin Neuropharmacol. 2004 Mar-Apr; 27(2):58-62.
    View in: PubMed
    Score: 0.031
  239. Pergolide in Parkinson's disease. Arch Neurol. 1983 Dec; 40(13):785-7.
    View in: PubMed
    Score: 0.030
  240. Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease. Hum Mol Genet. 2003 Dec 15; 12(24):3259-67.
    View in: PubMed
    Score: 0.030
  241. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol. 2003 Sep; 54(3):403-14.
    View in: PubMed
    Score: 0.030
  242. Association study of Parkin gene polymorphisms with idiopathic Parkinson disease. Arch Neurol. 2003 Jul; 60(7):975-80.
    View in: PubMed
    Score: 0.029
  243. Longitudinal outcome of Parkinson's disease patients with psychosis. Neurology. 2003 Jun 10; 60(11):1756-61.
    View in: PubMed
    Score: 0.029
  244. Parkin mutations and susceptibility alleles in late-onset Parkinson's disease. Ann Neurol. 2003 May; 53(5):624-9.
    View in: PubMed
    Score: 0.029
  245. Genetic polymorphisms of the N-acetyltransferase genes and risk of Parkinson's disease. Neurology. 2003 Apr 08; 60(7):1189-91.
    View in: PubMed
    Score: 0.029
  246. Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am J Hum Genet. 2003 Apr; 72(4):804-11.
    View in: PubMed
    Score: 0.029
  247. A 6-month trial of pergolide mesylate in the treatment of idiopathic Parkinson's disease. Adv Neurol. 1983; 37:75-83.
    View in: PubMed
    Score: 0.028
  248. Drug holiday in the management of Parkinson disease. Clin Neuropharmacol. 1982 Dec; 5(4):351-64.
    View in: PubMed
    Score: 0.028
  249. Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet. 2002 May 04; 359(9317):1589-98.
    View in: PubMed
    Score: 0.027
  250. A pure parkinsonian syndrome following acute carbon monoxide intoxication. Arch Neurol. 1982 May; 39(5):302-4.
    View in: PubMed
    Score: 0.027
  251. Pharmacology of hallucinations induced by long-term drug therapy. Am J Psychiatry. 1982 Apr; 139(4):494-7.
    View in: PubMed
    Score: 0.027
  252. Age at onset in two common neurodegenerative diseases is genetically controlled. Am J Hum Genet. 2002 Apr; 70(4):985-93.
    View in: PubMed
    Score: 0.027
  253. Complete genomic screen in Parkinson disease: evidence for multiple genes. JAMA. 2001 Nov 14; 286(18):2239-44.
    View in: PubMed
    Score: 0.026
  254. Association of single-nucleotide polymorphisms of the tau gene with late-onset Parkinson disease. JAMA. 2001 Nov 14; 286(18):2245-50.
    View in: PubMed
    Score: 0.026
  255. Weekly drug holiday in Parkinson disease. Neurology. 1981 Nov; 31(11):1460-2.
    View in: PubMed
    Score: 0.026
  256. CPK values in Parkinson's disease. N Engl J Med. 1981 Jun 25; 304(26):1608-9.
    View in: PubMed
    Score: 0.025
  257. Practical guidelines for drug holidays in parkinsonian patients. Neurology. 1981 May; 31(5):641-2.
    View in: PubMed
    Score: 0.025
  258. Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease. Arch Neurol. 2001 Feb; 58(2):249-54.
    View in: PubMed
    Score: 0.025
  259. Application of the Unified Parkinson's Disease Rating Scale in progressive supranuclear palsy: factor analysis of the motor scale. Mov Disord. 2000 Mar; 15(2):276-9.
    View in: PubMed
    Score: 0.023
  260. "On" freezing in Parkinson's disease: resistance to visual cue walking devices. Mov Disord. 2000 Mar; 15(2):309-12.
    View in: PubMed
    Score: 0.023
  261. Effects of central dopaminergic stimulation by apomorphine on speech in Parkinson's disease. Neurology. 2000 Jan 25; 54(2):458-62.
    View in: PubMed
    Score: 0.023
  262. Levodopa in the treatment of Parkinson's disease: a consensus meeting. Mov Disord. 1999 Nov; 14(6):911-3.
    View in: PubMed
    Score: 0.023
  263. The first miracle in neurodegenerative disease: the discovery of oral levodopa. Brain Res Bull. 1999 Nov-Dec; 50(5-6):377-8.
    View in: PubMed
    Score: 0.023
  264. Use of placebo surgery in controlled trials of a cellular-based therapy for Parkinson's disease. N Engl J Med. 1999 Sep 23; 341(13):988-92.
    View in: PubMed
    Score: 0.023
  265. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann Neurol. 1999 Sep; 46(3):419-24.
    View in: PubMed
    Score: 0.022
  266. The alpha-synuclein gene is not a major risk factor in familial Parkinson disease. Neurogenetics. 1999 Sep; 2(3):191-2.
    View in: PubMed
    Score: 0.022
  267. Factor analysis of the motor section of the unified Parkinson's disease rating scale during the off-state. Mov Disord. 1999 Jul; 14(4):585-9.
    View in: PubMed
    Score: 0.022
  268. Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson's disease. Mov Disord. 1999 Jan; 14(1):117-21.
    View in: PubMed
    Score: 0.021
  269. Poor visual discrimination and visual hallucinations in Parkinson's disease. Clin Neuropharmacol. 1998 Sep-Oct; 21(5):289-95.
    View in: PubMed
    Score: 0.021
  270. Clinical presentation and pharmacological therapy in corticobasal degeneration. Arch Neurol. 1998 Jul; 55(7):957-61.
    View in: PubMed
    Score: 0.021
  271. Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol. 1998 Jul; 55(7):969-78.
    View in: PubMed
    Score: 0.021
  272. Metric properties of nurses' ratings of parkinsonian signs with a modified Unified Parkinson's Disease Rating Scale. Neurology. 1997 Dec; 49(6):1580-7.
    View in: PubMed
    Score: 0.020
  273. Effect of stereotaxic intrastriatal cografts of autologous adrenal medulla and peripheral nerve in Parkinson's disease: two-year follow-up study. Exp Neurol. 1997 Oct; 147(2):510-7.
    View in: PubMed
    Score: 0.020
  274. The stability of carbidopa in solution. Mov Disord. 1997 Jul; 12(4):608-10.
    View in: PubMed
    Score: 0.019
  275. Treatment with fetal allografts. Neurology. 1997 Jun; 48(6):1737-8.
    View in: PubMed
    Score: 0.019
  276. Dopaminergic transplants in patients with Parkinson's disease: neuroanatomical correlates of clinical recovery. Exp Neurol. 1997 Mar; 144(1):41-6.
    View in: PubMed
    Score: 0.019
  277. Alpha-tocopherol in the ventricular cerebrospinal fluid of Parkinson's disease patients: dose-response study and correlations with plasma levels. Neurology. 1996 Oct; 47(4):1037-42.
    View in: PubMed
    Score: 0.018
  278. Genetic variability of the CYP 2D6 gene is not a risk factor for sporadic Parkinson's disease. Ann Neurol. 1996 Sep; 40(3):463-5.
    View in: PubMed
    Score: 0.018
  279. Case 1, 1996: rapidly progressive parkinsonism, incontinence, impotency, and levodopa-induced moaning in a patient with multiple myeloma. Mov Disord. 1996 May; 11(3):298-310.
    View in: PubMed
    Score: 0.018
  280. Prevalence of parkinsonian signs and associated mortality in a community population of older people. N Engl J Med. 1996 Jan 11; 334(2):71-6.
    View in: PubMed
    Score: 0.017
  281. Levodopa stability in solution: time course, environmental effects, and practical recommendations for clinical use. Mov Disord. 1996 Jan; 11(1):24-6.
    View in: PubMed
    Score: 0.017
  282. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015 Oct; 30(12):1591-601.
    View in: PubMed
    Score: 0.017
  283. MDS research criteria for prodromal Parkinson's disease. Mov Disord. 2015 Oct; 30(12):1600-11.
    View in: PubMed
    Score: 0.017
  284. Pramipexole in patients with early Parkinson's disease. Clin Neuropharmacol. 1995 Aug; 18(4):338-47.
    View in: PubMed
    Score: 0.017
  285. Factors predictive of the need for levodopa therapy in early, untreated Parkinson's disease. The Parkinson Study Group. Arch Neurol. 1995 Jun; 52(6):565-70.
    View in: PubMed
    Score: 0.017
  286. A practical approach to remote longitudinal follow-up of Parkinson's disease: the FOUND study. Mov Disord. 2014 May; 29(6):743-9.
    View in: PubMed
    Score: 0.015
  287. Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on-off' fluctuations. Neurology. 1993 Sep; 43(9):1698-703.
    View in: PubMed
    Score: 0.015
  288. Striatal extracts from patients with Parkinson's disease promote dopamine neuron growth in mesencephalic cultures. Exp Neurol. 1993 Mar; 120(1):149-52.
    View in: PubMed
    Score: 0.014
  289. Blinded evaluation confirms long-term asymmetric effect of unilateral thalamotomy or subthalamotomy on tremor in Parkinson's disease. Neurology. 1992 Jul; 42(7):1311-4.
    View in: PubMed
    Score: 0.014
  290. Core assessment program for intracerebral transplantations (CAPIT). Mov Disord. 1992; 7(1):2-13.
    View in: PubMed
    Score: 0.013
  291. Effect of MK-458 (HPMC) in Parkinson's disease previously untreated with dopaminergic drugs. A double-blind, placebo-controlled multicenter study. Clin Neuropharmacol. 1991 Aug; 14(4):322-9.
    View in: PubMed
    Score: 0.013
  292. The potential use of a dopamine neuron antibody and a striatal-derived neurotrophic factor as diagnostic markers in Parkinson's disease. Neurology. 1991 May; 41(5 Suppl 2):53-8; discussion 59-60.
    View in: PubMed
    Score: 0.013
  293. Clinical improvement in parkinsonian patients undergoing adrenal to caudate transplantation is not reflected by chromogranin A or basic fibroblast growth factor in ventricular fluid. Exp Neurol. 1991 Mar; 111(3):276-81.
    View in: PubMed
    Score: 0.012
  294. Autologous transplantation of adrenal medulla in Parkinson's disease. 18-month results. Arch Neurol. 1990 Dec; 47(12):1286-9.
    View in: PubMed
    Score: 0.012
  295. Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology. 1990 Oct; 40(10):1529-34.
    View in: PubMed
    Score: 0.012
  296. Disappearance of a putative DA-neuron antibody following adrenal medulla transplantation: relationship to a striatal-derived DA neuron trophic factor. Prog Brain Res. 1990; 82:693-7.
    View in: PubMed
    Score: 0.011
  297. Evaluation of a modified inverted walking stick as a treatment for parkinsonian freezing episodes. Mov Disord. 1990; 5(3):243-7.
    View in: PubMed
    Score: 0.011
  298. Hypersexuality with antiparkinsonian therapy. Clin Neuropharmacol. 1989 Oct; 12(5):375-83.
    View in: PubMed
    Score: 0.011
  299. Environmental factors and Parkinson's disease: a case-control study in China. Neurology. 1989 May; 39(5):660-4.
    View in: PubMed
    Score: 0.011
  300. An antibody in the CSF of Parkinson's disease patients disappears following adrenal medulla transplantation. Neurosci Lett. 1988 Nov 22; 94(1-2):192-7.
    View in: PubMed
    Score: 0.011
  301. The adrenal medullary transplant operation for Parkinson's disease: clinical observations in five patients. Neurosurgery. 1988 Jun; 22(6 Pt 1):999-1004.
    View in: PubMed
    Score: 0.010
  302. Hemiparkinsonism with hemiatrophy. Neurology. 1988 Apr; 38(4):527-30.
    View in: PubMed
    Score: 0.010
  303. Amantadine and motor fluctuations in chronic Parkinson's disease. Clin Neuropharmacol. 1987 Dec; 10(6):522-6.
    View in: PubMed
    Score: 0.010
  304. Pergolide mesylate: four years experience in Parkinson's disease. Adv Neurol. 1987; 45:547-9.
    View in: PubMed
    Score: 0.009
  305. Drug-induced myoclonus. Adv Neurol. 1986; 43:251-64.
    View in: PubMed
    Score: 0.009
  306. Pergolide mesylate: lack of cardiac toxicity in patients with cardiac disease. Neurology. 1985 Jun; 35(6):918-21.
    View in: PubMed
    Score: 0.008
  307. Levodopa-free periods ("drug holidays") in the management of parkinsonism. Adv Neurol. 1983; 37:33-43.
    View in: PubMed
    Score: 0.007
  308. Pergolide mesylate and idiopathic Parkinson disease. Neurology. 1982 Oct; 32(10):1175-9.
    View in: PubMed
    Score: 0.007
  309. Drug-induced extrapyramidal disorders - a neuropsychiatric interface. J Clin Psychopharmacol. 1981 Sep; 1(5):297-303.
    View in: PubMed
    Score: 0.006
  310. The effect of bromocriptine (BCT) on the on-off phenomenon. J Neural Transm. 1981; 52(1-2):41-7.
    View in: PubMed
    Score: 0.006
  311. Chronic agonist-induced hypersensitivity and on-off hyperkinesis. Ann Neurol. 1979 Sep; 6(3):277-8.
    View in: PubMed
    Score: 0.006
  312. Lergotrile in the treatment of parkinsonism. Neurology. 1978 Jul; 28(7):699-702.
    View in: PubMed
    Score: 0.005
  313. Recent advances in the biochemical pharmacology of extrapyramidal movement disorders. Adv Exp Med Biol. 1977; 90:21-47.
    View in: PubMed
    Score: 0.005
  314. Drug-induced asterixis in Parkinson disease. Neurology. 1982 May; 32(5):553-5.
    View in: PubMed
    Score: 0.002
  315. Complications of chronic levodopa therapy: long-term efficacy of drug holiday. Neurology. 1981 Apr; 31(4):473-6.
    View in: PubMed
    Score: 0.002
  316. Levodopa-induced myoclonus. Arch Neurol. 1975 May; 32(5):330-4.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.